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Abstract
Purpose: The Triple-Negative Breast Cancer (TNBC) subtype accounts for 15 percent of all
breast cancers. It is characterized by cancer cells that lack estrogen, progesterone, and
HER2/Neu receptors. TNBC is highly aggressive and deadly, and primarily affects younger
African-American women. Identification of microRNAs that can be used as biomarkers for
diagnosis, prognosis, and provide drug-able targets is the long-term goal of this study. The
objective of this study is to compare and contrast microRNA expression level profiles from
microarray (Partek Genomic Suite) and qPCR analysis performed on triple-negative breast
cancer versus normal breast tissue cell line in order to find potential biomarkers that could be
used for diagnosis, prognosis, and treatment of TNBC. Experimental Design: MicroRNA was
extracted from African-American derived normal (AG11132) and TNBC (HCC1806, HCC70,
and MB157) cell lines and subjected to microarray analysis using Partek Genomic Suite.
MicroRNAs 21, 34a, 103, 141, and let-7a were shown to be differentially expressed; up or
downregulated in TNBC cells vs. the normal breast tissue cell lines and were chosen for further
analysis. Prior to validation using qPCR, using pelleted cells from each cell line, microRNA was
extracted, converted to cDNA, and ran on the NanoDrop to determine purity and concentration
levels of the samples. Results: Partek Genomic Suite analysis revealed that microRNAs 21, 34a,
103, 141, and let-7a were differentially expressed in the TNBC cells when compared to the
“normal” breast cell line AG11132. Literature was consulted to choose microRNAs that have
been reported as playing a role in TNBC for further analysis using qPCR which validated the
microarray data. Conclusion: We show that TNBC cells have a differential microRNA
expression profile when compared to normal cells. Microarray analysis revealed that microRNA
expression profiles cluster the TNBC cells separately from the normal cells. We were also able
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to validate the findings of five microRNAs that were revealed in the microarray analysis to be up
or downregulated in the TNBC cells. The findings suggest that microRNAs could be used as
potential biomarkers to diagnose TNBC and could potentially be used as drug-targeted therapies
in the future.
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CHAPTER 1
INTRODUCTION
Breast cancer is the uncontrolled growth of abnormal tissues occurring in the breast.
Some tumors in the breast can grow slowly, potentially up to 10 years by the time a lump can be
felt, but some tumors are aggressive and grow much faster(Komen, 2015). Breast cancer mainly
occurs in women, but can occur in men less frequently.
Two types of breast cancer are ductal carcinomas and lobular carcinomas. 50 to 75% of
breast cancers begin in the milk ducts, while 10 to 15% begin in the lobules. These types of
breast cancer have four known subtypes: normal-like, luminal-like, HER-2-positive, and Basal like. Triple Negative Breast Cancer is a heterogeneous disease compromising of multiple tumors
that are associated with histological patterns and different biological and clinical behaviors.
Triple-negative breast cancer accounts for about 15 percent of all breast cancers. It is
characterized by cancer cells that lack estrogen, progesterone and HER2 receptors. For this
reason, these tumors do not respond to hormone therapies or HER2-targeted treatments.
MicroRNAs are short single stranded molecules that are involved in regulation of gene
expression and play a role in influencing the pathways that are known to be responsible for the
progression of many diseases such as cardiovascular disease and fibrosis. While microRNAs are
transcribed from genes, they do not encode for proteins. The function of microRNAs is to
prevent the translation of mRNAs into proteins be triggering degradation of these mRNAs.
Studies have shown that microRNA gene regulation is often not a decisive on and off switch but
a subtle function that fine-tunes cellular phenotypes that becomes more pronounced during stress
or disease conditions. MicroRNAs were first discovered in 1993 and have since been found in
nearly every biological system examined to date. They are highly conserved, demonstrating their
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importance to biological functions and cellular processes. According to the Sanger Institute, over
1000 microRNAs have been identified in humans. In the laboratory, microRNA are often used as
double stranded oligonucleotides, since they can be easily modulated.
According to a study published in 2014 by Gasparini et al, microRNAs can be used to
classify Triple-Negative Breast Cancer malignancy into six different subtypes, which could lead
to new screening methods, prognostic markers, and perhaps new targeted treatments for this
aggressive ad often form of breast cancer(Gasparini et al., 2014). The six different TNBC
subtypes were identified through gene expression profiling as: basal-like 1(BL1), basal-like
2(BL2), immunomodulatory, mesenchymal, mesenchymal stem-like, and luminal androgen
receptor-expressing. The most common of these subtypes is basal-like as it is often clinically
related to TNBC. All of these subtypes have different rates of incidence, risk factors, prognosis
and response to treatment. Sub classification is necessary to better identify molecular-based
therapeutic targets, select biomarkers, discover new drugs, and design clinical trials that will
enable alignment of TNBC patients to appropriate targeted therapies(Gasparini et al., 2014). It is
important to note, that while most microRNAs are down-regulated in cancer, they are upregulated in most of the other diseases.
The objectives of this study were:
1. To identify differential microRNA expression patterns in triple-negative breast cancer
cell lines and normal breast cell lines.
Approach: To evaluate, sort, and analyze microRNAs for similarities and differences
between the cell lines using raw data from microRNA array imported into Partek
Genomic Suite.
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2. To validate the microRNA expression in triple-negative breast cancer cell lines and
normal breast cell lines using Real-Time PCR.
Approach: Real-Time PCR will be used to confirm microarray analysis from Partek, by
identifying those microRNAs that present over, under, or no change in amplification from
the TNBC cell lines in comparison to the normal breast tissue cell lines.
Cancer is the second leading cause of death in the United States. It is estimated that there
will be 1.6 million new cases of cancer with over half a million resulting in death in 2014. Breast
Cancer, one of the most common types of cancer, accounts for about 12% of all cancer cases.
Breast cancer is a heterogeneous disease compromised of multiple tumors that are associated
with histological patterns and different biological and clinical behaviors. Triple-Negative Breast
cancer (TNBC) accounts for about 15 percent of all breast cancers. It is characterized by cancer
cells that lack estrogen, progesterone, and HER2/Neu receptors. For this reason, these tumors do
not respond to hormone therapies or HER2/Neu targeted treatments. There are no known
biomarkers for TNBC and therefore alternative modes of treatment are the long-term goal of this
study. MicroRNAs are short single stranded molecules that are involved in regulation of gene
expression and play a role in influencing the pathways that are known to be responsible for the
progression of many diseases. The objective of this proposal is to compare and contrast
microRNA expression level profiles from microarray and qPCR analysis performed on triplenegative breast cancer versus normal breast tissue cell line in order to find potential biomarkers
that could be used for diagnosis, prognosis, and treatment of TNBC.
Significance of Research
There is a lack of early diagnostic tools for triple-negative breast cancer which hinders
prognosis amongst all populations. TNBC is a heterogeneous disease where both gene and
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microRNA profiling studies have recently been carried out to determine and profile the different
molecular entities (D'Ippolito & Iorio, 2013). In recent years, microRNAs that are involved in
the synthesis of proteins related to proliferation, invasiveness, and metastasis have been
identified. The research proposed is significant because it identifies a rationale for experimental
analysis in lieu of a therapeutic application of microRNAs as treatment and prognostic
biomarkers for TNBC. This research is innovative, because we are addressing a question that is
limited in knowledge, but will bring profound awareness to the malignancy of TNBC as it
directly relates to African American Women as well as those of other races as well. This study
seeks to determine the microRNA expression profiles that are differentially expressed in TNBC
cells versus normal breast cells. The usage of Partek Genomic Suite for microRNA analysis and
RT-PCR/qPCR for further validation is an approach that has not been used for this type of data
analysis, making this innovative. Usage of cell lines, rather than the usage of breast tissue can be
used as the foundation for further research in that the cells can be grown indefinitely for
treatment responses; through the usage of individualized therapeutic options that can arise from
usage of cell lines.
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CHAPTER 2
LITERATURE REVIEW
2.1

Mechanisms behind Cancer, Breast Cancer, and Triple-Negative Breast Cancer
Cancer is the second leading cause of death in the United States; its incidence is

estimated at 1.6 million in 2014, with around 500,000 resulting in death. It affects both males
and females with susceptibility including factors such as age, environmental exposures and
genetic pre-disposition. Since cancer is a disease that typically occurs through the accumulation
of DNA mutations in cells, it commonly affects the elderly.
Cancer is described as many diseases characterized by uncontrollable growth of abnormal
or mutant cells that are able to invade other tissues and use their cells as sources of replication
for these mutant cells. Cancer is categorized into several different categories; carcinomas,
sarcomas, leukemia, lymphomas, melanomas, and the central nervous system cancers. New
cancer cases in the United States in 2015 were estimated at over 1.6 million cases with over
50,000 occurring in North Carolina. This estimate does not include carcinoma in situ
(noninvasive cancer) of any site except bladder and does not include basal cell and squamous
cell skin cancers because they are not required to be reported to cancer registries(Society, 2015).
Almost 600,000 Americans are expected to succumb to cancer per year at a rate of around 1600
individuals per day. Cancer is ranked at as the second most leading cause of death in the US,
preceded by heart disease at a rate of 1 out of every 4 individuals. The survival rate of
individuals with cancer is in more recent years at a rate of around 68%(Society, 2015).
One of the most common types of cancer is breast cancer, which accounts for
approximately 12% of all cancer. One type of breast cancer that occurs at a lower rate, but has
high mortality rates is Triple-Negative Breast Cancer. Triple-Negative Breast Cancer is
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commonly referred to as basal-like, while other breast cancer is commonly known as luminallike. According to Carey et al, basal-like breast tumors occurred at a higher incidence among
pre-menopausal African American patients compared with postmenopausal African-American
and non–African American patients(Carey et al., 2006). This leads to the conclusion that higher
prevalence of basal-like tumors correlates to African American women having a poor prognosis.
Receptor differences or lack thereof in triple-negative breast cancer, to that of typical breast
cancer give rise to different clinical treatments and manifestations.
The manifestation of tumors amongst African-American women when compared to
Caucasian women is a popular topic in Triple-Negative Breast Cancer due to a low incidence and
high mortality in this population. Carey et al, seeks to link the differing subtypes of cancer to the
population that it is found to be associated with the most (Carey et al., 2006). Subtypes identified
were: luminal A (ER+ and/or progesterone receptor positive [PR+], HER2−), luminal B (ER+
and/or PR+, HER2+), basal-like (ER−, PR−, HER2−, cytokeratin 5/6 positive, and/or HER1+),
HER2+/ER− (ER−, PR−, andHER2+), and unclassified negative for all 5 markers (Carey et al.,
2006). Outcomes were measured based on the subtype associated per race to the size of the
tumors, mitotic index, p53 mutation status, and specific survival-breast cancer. Although triplenegative breast cancer is commonly referred to as basal-like, Gazinska et al, showed that the
method of defining lesions, morphology, immunohistochemical markers or gene expression
expresses different tumor sets amongst basal-like and triple-negative breast cancer (Gazinska et
al., 2013). In order to successfully diagnosis, treat, and predict survival outcomes clear
approaches to the method of distinguishing between the two subtypes are necessary. Although
TNBC is a subtype of breast cancer, its clinical manifestations differ which has led to the need of
new therapeutic options in the treatment of this disease. Traditional breast cancer tools are not
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efficient on this subgroup due to these differences. Basal-like and triple-negative breast cancer
are commonly used interchangeable, however, the tumors associated with each subtype can vary,
making identification of TNBC subtypes important in order to adequately access diagnosis,
treatment, and prognosis.
2.1.1

Triple-Negative Breast Cancer

Triple-Negative Breast Cancer or TNBC as it is commonly referred to, is classified as
part of the basal-like invasive breast cancer subtype. This subtype is defined by the lack of
expression of estrogen, progesterone, and human epidermal growth factor receptors. TNBC is
characterized as an aggressive disease occurring at a rate of 15% that lacks therapeutic options
and poor prognosis. Triple- negative breast cancer occurring in African-American women is
more aggressive, diagnosed at a later stage, and carries poorer survival outcomes than those
cancer subtypes diagnosed in Caucasian women. According to Gazinska et al patients with triplenegative breast cancers have an increased risk of recurrence between the first and third years
after diagnosis and an increased mortality in the first 5 years after treatment (Gazinska et al.,
2013). At the moment the only therapy being used for system wide treatment of triple-negative
breast cancer is chemotherapy.
2.1.2

Biomarkers in Triple-Negative Breast Cancer

Currently, there are no known biomarkers for TNBC, and the reason it is more fatal in
African-American women is not understood. Biomarkers are biomolecules or processes which
can be diagnostic or prognostic indicators of the presence of cancer in the body. MicroRNAs are
small non-coding RNA molecules which are involved in the process of gene regulation and are
located in the intron regions of coding and non-coding genes. Biomarkers have been defined as a
characteristic that is objectively measured and evaluated as an indicator of normal biological
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process, pathogenic process, or pharmacologic responses to a therapeutic intervention(Strimbu &
Tavel, 2010). Despite the increased progress in part to new detection methods and therapies,
breast cancer is still the leading cause of death related to cancer in women around the world. Not
only is it due to environmental factors, but genetics plays a major role in the mortality of this
disease(Stevens, Vachon, & Couch, 2013).
Previous studies used gene profiling to define the specific characteristics associated with
different cancers, thus leading to their treatment and prognosis. In the recent years small noncoding RNAs, microRNAs have been found to play are role in many diseases, with cancer being
one of them. Since their ability to potentially target any human mRNA, it is likely that
microRNAs are involved in almost every biological process, including cell cycle regulation, cell
growth, apoptosis, cell differentiation and stress response. The involvement of microRNAs in the
biology of human cancer is supported by an increasing body of experimental evidence that has
gradually switched from profiling studies. This implicates microRNAs as biomarkers for
diagnosis, treatment, and prognosis. Concerning breast cancer, a pilot study performed by Roth
et al, provided the first evidence that tumor-associated circulating microRNAs are elevated in
the blood of breast cancer patients and associated with tumor progression (Roth et al., 2010).
MicroRNA-34a was one of the microRNAs identified to be associated with primary breast
cancer and metastatic disease. This particular microRNA is known to be an inhibitor of tumor
progression in both colon and lung cancer. The microRNA-34 family regulates cell cycle
progression, cellular senescence and apoptosis and, as a consequence, could affect biological
features of TNBC (Svoboda et al., 2012). This further indicates microRNA-34a as a potential
biomarker for TNBC, as it comes from a family that all have potential roles in this disease.
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MicroRNAs are emerging as vital entities in the field of cancer. Triple-Negative Breast
Cancer is disease that cannot be approached using the same methodologies of identification,
classification, or treatments as the other subtypes of breast cancer. Its high rate of mortality must
be addressed in order to increase the prognosis, treatment, and prognosis for those suffering with
the disease. The ability of microRNAs to be modulated transcriptionally and post
transcriptionally means they can play an active role on any RNA, increasing the possibly of these
small non-coding RNAs as biomarkers for such a prevalent disease.
2.2

Micro Ribonucleic Acid
MicroRNAs (microRNAs) were discovered in 1993, when the microRNA lin-4 was

determined to down-regulate expression of the gene lin-4 in Caenorhabditis elegans. The
discovery of the microRNA let-7 in 2000, with homologs in other species including humans,
showed that microRNAs are quite common in eukaryotes. Lin-4 and let-7 act as posttranscriptional repressors of their target genes when bound to their specific sites in the 3’
untranslated region of the target mRNA(R. C. Lee, Feinbaum, & Ambros, 1993). MicroRNAs
are short non-coding regions of RNAs that regulate gene expression post-transcriptionally.
It has been determined that microRNA expression is often exaggerated in diseases and
they regulate many thousands of genes. These potential therapeutic targets however, have not
been extensively validated. While it is know that they are post-transcriptionally modified the
exact mechanisms behind the roles of microRNA expression are not fully understood.
MicroRNAs are a major class of small endogenous RNA molecules that post-transcriptionally
inhibit gene expression; ranging in size from 18-24 nucleotide bases in length(O'Day & Lal,
2010). They play a role in many cellular processes through regulation of gene expression.
Through stability reduction in mRNAs, microRNAs influence the function of genes that mediate
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processes such as tumorgenesis(O'Day & Lal, 2010). These processes play different roles within
the cell; inflammation, cell cycle regulation, stresses responses, apoptosis, invasion, and
differentiation. Since, microRNAs play an active role in regulation of gene expression; they
influence the ability of cells to increase or decrease production of gene products such as, RNA or
Protein.
MicroRNAs are able to be modulated, suggesting their ability to play a role in diagnosis,
treatment, and prognosis of those suffering from this disease (John et al., 2004). MicroRNAs
have been found to be directly involved in human cancers, including lung, breast, brain, liver,
colon cancer and leukemia. In addition, some microRNAs may function as oncogenes or tumor
suppressors in tumor development (Melo & Esteller, 2011). Oncogene and tumor suppressors are
the major factors that promote and demote tumor development, the role of microRNAs would
suggest an active role in tumorgenesis and transformation of cells. The location of microRNAs
on genes, their expression levels, and/or deletion are also indication of cellular transformation;
benign to malignant. Studies that seek to identify microRNAs associated with distant relapse-free
survival which provides independent prognostic information and are not surrogates of previously
identified prognostic covariates through microRNA expression are not emerging(Buffa et al.,
2011). MicroRNA regulation and expression will allow for new therapeutic strategies,
mechanisms of tumor develop, and manifestation of cellular transformation to be used in the
fight against cancer. Currently, microRNAs expression profiles are emerging as classification
and identification strategies to be used as potential therapeutic interventions.
2.2.1

MicroRNA Biogenesis & Gene Regulation

MicroRNAs play diverse roles within the pathways in which they interact in. processing
and gene regulation of microRNAs results in either mRNA degradation or translation which
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resulting in protein processing and degradation. This process can be broken down into a few
steps. The microRNA precursor folds back onto itself and the enzyme Dicer moves along the
dsRNA, cutting it into shorter segments(Y. Lee, Jeon, Lee, Kim, & Kim, 2002). One strand of
the dsRNA is degraded, while the other microRNA strand associates with a protein complex.
This microRNA is able to base-pair any target mRNA containing the complementary sequence.
This microRNA-protein complex prevents gene expression by either degrading the target mRNA
or by blocking its translation(Y. Lee et al., 2002). This process demonstrates the normal role in
which microRNAs play in gene regulation.
2.2.2

MicroRNAs in Triple-Negative Breast Cancer

TNBC is a heterogeneous disease where both gene and microRNA profiling studies have
recently been carried out to determine the different molecular entities (D'Ippolito and Iorio
2013). Although the identification and classification of MicroRNAs has been established their
exact mechanisms within the various pathways that leads to cancer have yet to be extensively
studied. MicroRNAs are being classified to characterize the varying molecular entities.
Currently, several microRNAs; microRNA-145, microRNA-21, and the let-7 family may be
involved in the molecular basis of Triple-Negative Breast Cancer have been identified (Iorio et
al., 2005). Such analysis has already started to show promising results as their potential usage of
biomarkers, indicators of prognosis and diagnosis in TNBC. MicroRNAs are small non-coding
RNA molecules that are responsible for regulation of cellular function, both transcriptionally and
post-transcriptionally. This is important because they have prominent roles in the pre- and postprotein pathways, which ultimately have the greatest effect on cancer, specifically TNBC. The
P53 pathway is associated with microRNA-21, microRNA-34a, microRNA-141, microRNA103, and let-7a and their interactions with genes and their products such as MDM2, GADD45
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and BAX(Stevens et al., 2013). MicroRNA-144 and microRNA-27b interact with the MAPK
pathway to target MAPK8 and MAPK14, respectively (Buffa et al., 2011). Chen & Bourguignon
et at, demonstrates the role of microRNA-21 in the CD44 pathway where it plays a role in
increasing anti-apoptosis protein Bcl-2 and up-regulates inhibitors of the apoptosis family of
proteins (IAPs) as well as chemo-resistance in MDA-MB-468 cells (Chen & Bourguignon,
2014). These pathways help to elucidate some of the roles that microRNAs are involved in
within the body. MicroRNAs are also prevalent in other diseases and cancers as well. Di Fazio et
al, demonstrates a down-regulation of hsa-let-7b in liver cancer lines (Di Fazio et al., 2012). The
let-7 family is known to be down-regulated in TNBC. It is known that microRNAs are
commonly downregulated in cancer, Jannson et al, suggests a down-regulation of microRNAs in
colorectal, gastric, esophageal, and prostate cancer(Jansson & Lund, 2012). While, microRNAs
are most commonly known for their roles in cancer, they have also been implicated in other
diseases such as neurodevelopmental disease, cardiovascular disease, autoimmune disease, liver
disease, skeletal disease, and skin disease. According to John et al, microRNAs target FMRP
genes, genes code for the protein associated with the neurodevelopmental disease, Fragile X
syndrome (John et al., 2004). The roles in other diseases though far less studied, help to provide
important contributions to the elucidation of microRNAs. Ardekani et al, demonstrates
microRNAs in a variety of diseases such as: let-7a role in vasculogenesis; microRNA-155
contributes to monocyte expansion during inflammation in rheumatic arthritis; microRNA -125
in Alzheimer’s disease; microRNA-141 in systemic lupus erythematosus; and microRNA-203 in
Psoriasis(Ardekani & Naeini, 2010).
The ability of these MicroRNAs to be modulated, suggests their ability to play a role in
diagnosis, treatment, and prognosis of those suffering from this disease. MicroRNAs have been
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found to be directly involved in human cancers, including lung, breast, brain, liver, colon cancer
and leukemia. In addition, some microRNAs may function as oncogenes or tumor suppressors in
tumor development (8). Oncogene and tumor suppressors are the major factors that promote and
demote tumor development, the role of microRNAs would suggest an active role in tumorgenesis
and transformation of cells. The location of microRNAs on genes, their expression profiles,
and/or deletion are also indication of cellular transformation (benign to malignant). Studies that
seek to identify microRNAs associated with distant relapse-free survival(DRFS) that provide
independent prognostic information, and are not simply surrogates of previously identified
prognostic covariates through microRNA expression are not emerging (1). MicroRNA regulation
and expression will allow for new therapeutic strategies, mechanisms of tumor develop, and
manifestation of cellular transformation to be used in the fight against cancer. Currently,
microRNAs expression profiles are emerging as classification and identification strategies to be
used as potential therapeutic interventions.
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CHAPTER 3
METHODOLOGY
3.1

Cell Lines
Triple-negative breast cancer cell lines HCC1806, HCC70, and MDA-MB-157 were

purchased from American Type Culture Collection (Manassas, VA). Normal cell line A11132
was purchased from Coriell Institute for Medical Research (Camden, NJ). HCC1806 is a triple
negative basal cell line that was derived from a 60 year old African American female initiated in
1995 from a tumor classified as TNM stage IIB grade 2. This patient was diagnosed with
acantholytic squamous carcinoma. HCC1806 is negative for estrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). HCC7O is a
luminal cell line derived from a 49 year old African American female initiated in 1992 from a
tumor that was classified as a TNM stage IIIA, grade 3. This patient suffered from invasive
primary ductal carcinoma. HCC70 expresses the ER and over expresses HER2, but does not
express PR. MDA-MB-157, a triple negative cell line, derived from a 44 year old African
American female suffering from medullary carcinoma. MDA-MB-157 is negative for ER, PR,
and said to express HER2+. Normal breast cell line, AG11132 was derived from a 16 year old
African American female obtained in 1978, during a reduction mammoplasty. AG11132
expresses ER, PR, and HER2. All cell lines were derived from the breast tissue of African
American female ages ranging from 19-60 years of age. Cell lines HCC1806 and HCC70 were
both grown in RPMI-1640 (Thermo Scientific; Rockford, IL) containing 10% fetal bovine serum
(FBS) and 1% penicillin and streptomycin (P/S) (Hyclone Laboratory; Logan Utah). AG11132
was grown in MEGM (Lonza; Walkersville, MD). MDA-MB-157 was grown in L-15 (Thermo
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Scientific; Rockford, IL). All cell lines were maintained in 5% CO2 at 37° C. To successfully
grow cell, cells were collected carefully at a confluency of 100,000 cells per tube.
3.2

Counting &Pelleting Cells
All media from primary culture on 10 cm plates was removed with a sterile aspirator.

Adherent cells were washed twice with 2 ml of 1X Phosphate Buffer Saline (PBS).
Approximately 2 ml of trypsin/EDTA (Hyclone Laboratory; Logan, Utah) was added to the
plates and incubated in a 37°C incubator until cells detached from the plate. 1 ml of
trypsin/EDTA solution was added to culture in 6 cm plate. Plates were placed in a 37°C
incubator for 1.5 minutes. Cells were examined using an inverted microscope making sure all
cells were detached from the surface. A volume of 4 ml of complete medium was added to each
plate to stop trypsin/EDTA function. The cellular suspension were removed from the plate and
added to 15 ml conical tubes. Each tube was then centrifuged for 5 minutes at 4000 rpm at room
temperature. 10 uL of cell suspension was extracted from the conical tubes and placed it into the
sample introduction point of the hemocytometer. The hemocytometer was placed on the
microscope and the counting grid was placed into focus. Three to four grid areas were counted
and averaged the calculations involved in counting the cells are shown below:
Total number of cells = Average cell count * 104 cells/ml * total volume (ml)
The remainder of cell suspension was aliquoted and placed into labeled 1.5 ml sterile
micro centrifuge tubes. The tubes were centrifuged for an additional 5 minutes at 1500 rpm at
room temperature. Supernatant was removed from cell pellets. Tubes were then stored at -70°C
until pellets were sent off for microarray analysis.
3.3

Microarray Analysis
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Prior to usage of Partek Genomic Suite, microarray analysis of microRNAs from breast
cell lines were performed. MicroRNA hybridization to microarray slides was performed at
Beckman Coulter (Morrisville, NC). Eight human cell tissue culture pellets used in this study
were sent to Beckman Coulter Genomics (Morrisville, NC) in accordance with Beckman Coulter
Genomics’ specifications for microRNA expression profiles of each cell line. One hundred
nanograms of total RNA were labeled with the fluorescent dye Cyanine 3-pCp (Cy3) 23 using
the microRNAs Complete Labeling Kit (Agilent Technologies, Palo Alto, CA) following the
manufacturer’s protocol. Cy3-labeled RNA from each sample was hybridized to an Agilent
Human microRNAs Microarray 8x15K Release 14.0 (029297) arrays. The hybridized array was
then washed and scanned and data was extracted from the scanned image using Feature
Extraction version 10.7 (Agilent Technologies). Details of samples that were hybridized to each
were coded according to bar-coded microarray.
Data generated from the microarray analysis were sent back to North Carolina
Agricultural and Technical State University for analysis using Partek Genomic Suite. Normal
cell lines microRNA were used as a control and were compared to the cancerous tissue cells.
3.4

Bioinformatics Software (Partek Genomic Suite)
Partek Genomic Suite incorporates your own data and allows for analysis of this

information in a variety of different methods. Importation of data into Partek can be done in
several different ways; data can come from different array chips (Agilent or Affymetrix) and text
files. We used the text file importation method which carried us through a simple set of steps
where we selected the data that we wanted to include in analysis in Partek Genomic Suite. The
process for using chips such as Affymetrix or Agilent has several more dialogue boxes that must
be completed prior to importation of files. Controls used in this experiment were designated as
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normal breast tissue cell line AG1132 (1&2) and TNBC cancer cell lines were identified as
MDA-MB-157(1&2) and HCC1806 (1&2). HCC70 (1&2) was previously considered as luminal;
however, it has now been classified as a TNBC cell line. All the raw data was combined initially
and had to be removed through filtering. The mean & median signal and gene name are the
categories that were filtered out of the original cell line data. From this data the individual cell
lines were then filtered out individually and merged based on the cell line type. There were two
sets of data for each cell line as it was run on the microarray chip twice. Finally, all the cancer
cell lines were combined onto one spreadsheet. This was done using the merge spreadsheet
function of Partek. The newly merged spreadsheet will then have other files merged into it and
saves as existing name of first file. Once the file is merged in Partek, the file that has the existing
information added will be marked with an asterisk. In order to save it, right click on the file and
click Save as to create a new file.
3.4.1

Analyzing Partek Data

AG1132 1&2 were merged, followed by MB157 (1&2), HCC1806 (1&2), and HCC70
(1&2) were merged with each other. Next, all three of the triple negative breast cancer cell lines
were merged with each other. Files were saved based on cell line name with the word “Filter”
placed in front. When merging some of the TNBC cell line data the gene name category was lost,
this was remedied by simply inserting a column into the Partek spreadsheet. In order to insert a
column, any column can be selected, right click and select add column. Next chose its location
and change the column configuration to text for the type and the string size needs to be 31. This
is important if the amount of data entered into the column has more than 31 characters, it will be
rejected in Partek. These factors can be changed based on the information that is being used,
however, if it is not the same parameters for each column added, and then the configuration
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properties must be configured individually. The usage of Partek is for a more accurate
assessment of the similarities and differences seen among the normal-like and cancer cell lines;
specifically to determine which microRNAs are down-regulated or up-regulated and use this
information along with previous research and scholarly journals to determine if these
microRNAs are potentially important in cancer. Partek has several workflows that provide the
user with multiple options, including microRNA Expression Workflow. In the top right had
corner above the spreadsheet there is a drop-down menu that contains the workflows available
for usage. After selecting microRNA expression, choosing a file to import is the next step. Since
the text files have already been imported, load from existing file is selected. After the file is
opened the next option is to add attributes, this however will not work with the text files, so
categorical attributes was selected. Categorical attributes shows all the microRNAs (well over
13,000), but each must be individual clicked and dragged to the add attribute column and none
can be left unassigned. For this reason, this skip was skipped. The edit sample information step,
brings up a dialogue box, however no results are produced from it. Next, select “Choose sample
ID column”, where Gene Name was chose and click ok. QC Metrics indicated that it could only
be used for Affymetrix gene expression arrays of QC metrics spreadsheets. Sample histogram
plots were derived in the next step followed by, PCA or Principal Component Analysis Mapping.
The latter showed some areas of data represented by large clusters along with individual clusters
scarcely distributed.
The next step was analysis which detected differentially expressed microRNAs by
selecting all response variable and experimental factors. This step was incomplete with text file
usage. Visualization of microRNAs showed clusters based on significant microRNAs. This is
done by specifying the type of clustering, in which hierarchical clustering was selected with
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normalized expression. MicroRNA Integration combines microRNAs with their mRNA targets;
finds over-expressed microRNAs target/sets, and correlating microRNA and mRNA data.
Biological Interpretation provides gene set analysis while Pathway Analysis shows a Partek
pathways detailing Proteoglycans in Cancer based on the microRNAs provided in the program.
Hierarchical Clustering is a method of clustering analysis wherein sets of values linked to
specific entities are analyzed in order to build a hierarchy of clusters. It is important to determine
the clustering of the microRNAs because expression patterns of the differentially expressed
microRNAs amongst normal breast tissue cell lines to TNBC cell lines. There are 16 columns
on the spreadsheet with each four representing a different cell line, each ran twice. Columns 1-4
are indicative of normal-like AG1132 (1&2), 5-8 are MB157 (1&2)), columns 9-12 are
HCC1806 (1&2) and Columns 13-16 are indicative of HCC70 (1&2). Figure... below displays
the hierarchical clustering for the data described above.
3.4.2

Comparison of Cell Lines using Partek Genomic Suites

AG11132 is the normal breast tissue while the other three cell lines are TNBC, so
AG11132 will serve as the baseline or control for these comparisons. Any deviations from the
normal can indicate cancer prevalence due to a change in expression of certain microRNAs.
These deviations can be large, small, and vary across the TNBC cell lines. Each one of these
combined data fields contains over 13.000 microRNAs, thus making extraction of values for
comparison extremely hard and tedious. Since values range from the high thirties to well over
fifty-thousand for the mean and max values there needs to be values set in order to facilitate
comparisons. It was found that several controls were used on the Agilent chip, so in order to
eliminate some of the larger values these controls needed to be removed. The following table
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depicts the control probes and their associated descriptions used on the Agilent microRNA
microarray chip.
Table 3.1 Removal of Controls used on Agilent Microarray Chip.
Other
Compute background Drosophila Sequences & Dim in
human
levels and noise
the absence of that target
RNAs
DarkCorner

SCorner3

hur_1

NC1_00000197
NC1_00000215
NC2_00079215
NC2_00092197
NC2_00106057
NC2_00122731
NegativeControl

dmr_285
dmr_3
dmr_308
dmr_316
dmr_31a
dmr_6

hur_2
hur_4
hur_5
hur_6
mr_1
dmr_6

Poly-A RNA &
Automatic Gridding
microRNABrightCorner3
0

Table 3.1 displays column 1 which contains the negative controls responsible for
computation of background levels and noise and contains signals at or around the background
levels. Column 2 represents sequences that are both drosophila and dim in the absence of the
target. These are identified as control type =1. Column 3 indicated other human RNAs that are
not microRNAs, but are commonly present in human samples. These probes can be either bright
or dim and are identified as control type =1. The final column contains the last probe which is a
poly T sequence that hybridizes to polyA RNA. This probe will typically be quite bright for any
total RNA and assist with the automatic gridding of the arrays. This probe is also control
type=1.
Once these controls were identified the next step was to remove them from the data in
Partek. This is a significant amount of data so; individual removal would be hard since they all
have several different components. Using Partek’s Find/Replace tool allows the individual to

23
find each of the controls within the cell lines and select them all. Next, with the Find/Replace
Dialogue box still open the data is highlighted on the Partek spreadsheet allowing the user to
right click and select delete to remove the corresponding data. This was done for all of the
controls. While this did only eliminate around one-thousand values out of thirteen thousand,
many of those values were very large.
Now that the controls were removed it was time to determine the values to set so that the
over/under expressed microRNAs could be identified. Using Partek’s stat menu the g-mean
signal values were assessed. The g-mean signals were found to be 30, 5233, 39, & 54 for the
minimum, maximum, median, and mean, respectively. This was really unhelpful because values
greater than the minimum, but less than the maximum were the majority of the values present.
So, through sorting of the microRNAs within the AG11132 cell line it was deduced that a
standard for values greater than 95 and those less than 95 would be the baseline for comparison.
Determination of under and over expression of these values could only be determined
through literature reviews. Using the mean, median, and averages computed from the AG11132
cell line did not help to narrow down the list of microRNAs. So, based on the general amounts of
values present it was found the microRNAs found to be greater than or less than 95 were shown
to be significantly expressed. For this reason 95 was the baseline used for this study. Baseline
associated with the literature review of microRNAs within this value shown to play a role in a
variety of different cancers, not just TNBC.
While I was able to limit the number of microRNAs to a relatively small number using
this method, I did not want to risk leaving out any significant microRNAs for the sake of
accuracy. So, I went through all twelve-thousand microRNAs looking for differentially
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expressed values and then reviewed literature for relevance. From this microRNAs with known
relationships to TNBC and other associations to cancer such as proliferation and metastases were
identified. Of these I found 32 differentially expressed microRNAs were identified as being
either over or under expressed in cancer. It is important to note that while these select
microRNAs show over or under-expression all the values across the cell lines may not show an
alarming increase or decrease pointing toward its expression. For this reason the microRNA list
was further narrowed down to a select number of microRNAs where the literature is consistent
with the values obtained from Partek Genomic Suite.
Figure 3.4 located in the appendix, shows the diagram created by Pathway Enrichment
Analysis. The diagram is a product of Partek’s Enrichment Analysis is based on the microRNAs
in relationship to their gene associations. Pathway enrichment was run initially on all of the
microRNAs, when the list was narrowed down to 32 and it was also run when the final seven
microRNAs to be used for RT-PCR validation was ran the associated pathways did not change.
3.5

Preparation for Real-Time PCR (microRNA extraction; NanoDrop; cDNA)
Prior to the start of RT-PCR there were preparation steps that had to occur. Cells were

grown to 90 to 95 percent confluency and then pelleted and stored at (-80⁰). Using the miRNeasy
Mini Handbook the previously frozen down pellets are disrupted by addition of QlAzol Lysis
Reagent. It is important to loosen the cell pellet to gain an efficient lysis and increased RNA
yields. Next, chloroform is added to the tube containing the homogenate and capped securely
prior to shaking the tube vigorously for 15 seconds in order to obtain the subsequent phase
separation followed by centrifugation. After centrifugation, the sample separates into 3 phases:
an upper, colorless aqueous phase containing RNA, a white interphase, and a lower, red, organic
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phase. Transfer the upper aqueous phase to a new collection tube. This was followed by several
steps wash and centrifugation steps. Following this step, remove the RNeasy Mini spin column
from the collection tube carefully so the column does not contact that flow-through, to prevent
ethanol carryover. Next, place the RNeasy Mini spin column into a new 2ml collection tube and
discard the old collection tube with the flow-through. Centrifuge in a micro centrifuge at full
speed for 1 min. this step helps to eliminate any possible carryover of Buffer RPE or any residual
flow-through remains on the outside to the RNeasy Mini spin column from the previous step.
The RNeasy Mini spin column is transferred to a new 1.5 ml collection tube and 30 –
50ul RNase-free water is added directly onto the RNeasy Mini spin column membrane and
centrifuged. If the expected yield is > 30 ug, repeat this step with a second volume of 30 – 50 ul
of RNase-free water. Elute into same collection tube. To obtain a higher total RNA
concentration, this second elution step may be performed by using the first elute from the
previous step. The yield will be 15- 30 % less that the yield obtained using the second volume of
RNase-free water, but the final concentration will be higher. It was discovered through
significant testing that the pellets for TNBC cell line MB157 were significantly degraded and
highly unstable, so we were unable to use it for the RT-PCR portion of this study.
Usage of the NanoDrop 1000 spectrometer allowed for RNA and DNA purity of nucleic
acid from samples to be readily checked for concentration and quality. Selecting the nucleic acid
application module and using 1ul samples sufficiently display accurate and reproducible results
when measuring aqueous nucleic acid samples. After the microRNA extraction, RNA-40 for
RNA was selected as the parameter for the type of nucleic acid being measured. The ratio that is
of most important is the 260/280 ratio wherein a ratio of around ~ 2.0 is generally accepted as
pure for RNA. Absorbance of the sample concentration is also an important factor. The
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following table represents the values for the first run of the microRNA extraction for a specific
set of pellets. For the 260/230 ratio is a secondary measure of nucleic acid purity and values
ranging from 1.8-2.2 are generally accepted as pure. The ng/ul sample concentration is made on
the absorbance at 260 nm and the selected analysis constant.
Next, was the cDNA synthesis step, the cDNA Synthesis kit includes 5x iScript reaction
mix, iScript reverse transcriptase, Nuclease-free water, and RNA template (100 fg to 1 ug total
RNA). The following figure represents amounts used in this process:

Figure 3.1 cDNA Reagents and Cycle Conditions
Figure 3.1 displays the reagents used to convert the microRNA that was extracted in the
previous step to cDNA. It also displays the cycle conditions for conversion of cDNA using the
Bio-Rad Thermocycler.
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Following cDNA synthesis another NanoDrop run was performed. , DNA-40 for DNA
was selected as the parameter for the type of nucleic acid being measured. The ratio that is of
most important is the 260/280 ratio wherein a ratio of around ~1.8 is generally accepted as pure
for DNA. The 260/230 ratio is a secondary measure of nucleic acid purity and values ranging
from 1.8-2.2 are generally accepted as pure. The ng/ul sample concentration is made on the
absorbance at 260 nm and the selected analysis constant. While there is not a specific range for
the concentration, after performing the experiment many times you expect each cell line to
display values within a specific range.
3.6

Real-Time PCR
Real-Time Quantitative Reverse Transcription (qRT-PCR) enables reliable detection and

measurement of products generated during each cycle of PCR process. Our approach utilized the
data from Partek will be further tested for accuracy through verification of expression levels
using Real-Time Polymerase Chain Reactions. Amplification of the varying microRNAs will
demonstrate potential biomarkers in TNBC. We chose to work with five primers; HsamicroRNA-103, Hsa-miR-21, Hsa-miR-141, Hsa-miR-34a, and Hsa-let-7a. These primers were
substituted in the reaction below as demonstrated in the reagents. Using the reagents and cycle
conditions in Figure 3.2 RT-PCR is performed.
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Figure 3.2 Real Time PCR Reagents and Cycle Conditions
Figure 3.2 illustrates the reagents and their associated volumes which were need for each
of the 5 primers that were used in the RT-PCR reactions. It also displays the cycle conditions in
which the machine was setup to run per each reaction. Real-Time PCR reaction expression levels
are indicated by Cq values. Cq is a quantification cycle that corresponds to a threshold cycle; the
point where the fluorescence signal is high enough to be differentiated from the background
noise. When there is more DNA or high expression levels then there are in fact fewer cycles,
which result in lower Cq values. However, when there is less DNA or lower expression levels
then more cycles occur, demonstrating higher Cq values.
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CHAPTER 4
RESULTS
To identify differential microRNA expression patterns in Triple-Negative Breast

4.1

Cancer cell lines and Normal Breast Cancer cell line.
One of the first figures made in Partek Genomic Suite was a hierarchical clustering of the
g-mean signals from all of the cell lines imported from the microarray chip shown in figure 4.1
below.

Hierarchical Clustering

of g-mean miRNA signal

HCC1806 g-Mean
Signal

AG11132 g-Mean
Signal

AG11132 g-Mean
Signal

HCC70 g-Mean
Signal

HCC1806 g-Mean
Signal

MB157 g-Mean
Signal

MB157 g-Mean
Signal

HCC70 g-Mean
Signal

values all cell lines.

Figure 4.1 Hierarchical Clustering of g-mean signal values
Figure 4.1 displays the hierarchical clustering from all four of the cell lines used on the
microarray chip. Each one of the cell lines was run twice for a total of eight individual sets of
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values. While cell lines MB157 and AG11132 are clustered together, HCC 1806 and HCC 70 are
clustered separately. This is due to the latter cell lines being extracted from two different pellets
and the prior being extracted from the same pellet.
Table 4.3 located in the appendix demonstrates the 32 microRNAs found to be
differentially expressed and associated with breast cancer according to literature reviews.
AG11132 is the normal-like breast tissue cell line and MB157, HCC1806 and HCC70 are the
Triple-Negative Breast Cancer cell lines. The figure also indicates the relative expression levels
of these microRNAs amongst the cell lines.

Hierarchical Clustering

Figure 4.2 Hierarchical clustering of 32 differentially expressed microRNAs
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Figure 4.2 is based on data from table 4.3found in the appendix; it displays the 32
differentially expressed microRNAs identified in Partek Genomic Suite. It demonstrates the
familiar relationships of microRNAs amongst the different cell lines and also displays the
clustering amongst the different microRNAs. From the 32 microRNAs previously selected, we
further narrowed the microRNAs list down using literature reviews. Hsa-microR-21 and the let-7
family are two of the most well-known microRNAs. Hsa-microRNA-34a and Hsa-microRNA103 are consistently differentially expressed across the Triple-Negative Breast Cancer cell line in
comparison to the normal breast tissue cell lines. Hsa-microRNA-141 did not show consistency
based on the data from Partek Genomic Suite, but based on literature findings, it is a significant
microRNA associated with TNBC.
Table 4.1 Significantly Expressed MicroRNAs
MicroRNAs

AG11132

AG11132

MB157

MB157

HCC1806

HCC1806

HCC70

HCC70

Signal

Classification

Signal

Classification

Signal

Classification

Signal

Classification

HsamicroRNA34a

256

Normal

48

Down
Regulated

98

Down
Regulated

68

Down
Regulated

HsamicroRNA141

48

Normal

47

Down
Regulated

55

Up
Regulated

56

Up
Regulated

HsamicroRNA21

92

Normal

85

Down
Regulated

108

Up
Regulated

122

Up
Regulated

HsamicroRNA103

103

Normal

121

Up
Regulated

121

Up
Regulated

148

Up
Regulated

Hsa-let-7i

158

Normal

148

Down
Regulated

225

Up
Regulated

107

Down
Regulated

Hsa-let-7f

471

Normal

380

Down
Regulated

233

Down
Regulated

198

Down
Regulated

Hsa-let-7a

1299

Normal

573

Down
Regulated

743

Down
Regulated

602

Down
Regulated
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While using Partek Genomic Suite we found 32 differentially expressed microRNAs
which have been reported to play roles in cancer. Table 4.1 lists the 7 differentially expressed
microRNAs and their average g-mean signal value which indicates their expression levels in the
TNBC cell lines (HCC1806, HCC70, and MB157) in comparison to the normal breast tissue cell
line AG11132. Through literature research we were able to narrow our search down to 7 TNBC
specific microRNAs as noted in figure 4.1.

Hierarchical Clustering

Figure 4.3 Hierarchical Clustering of 7 Differentially Expressed MicroRNAs
Figure 4.3 demonstrates the familial relationships of the 7 differentially expressed
microRNAs amongst the four cell lines. The color intensity is based on the differences amongst
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the g-mean values of the microRNAs. E.g. HSA-let-7a demonstrates a bright red hue in the
AG11132 cell line while the color is a duller red amongst the remaining cell lines. This color
change indicates a value that is higher in the normal breast cell lines in comparison to the TNBC
cell lines. The higher the values amongst each microRNA per cell line the redder the color; while
the blue it is, the less the value is compared to the other values.
Figure 4.4 also located in the appendix also, demonstrates a figure from Partek,
enrichment analysis. It is based on all of the microRNAs found on the microarray chip. It shows
associated pathways and microRNAs associated with them. This analysis provided the same
diagram when run using either the 32 or 7 microRNAs found to be differentially expressed using
Partek. In order to access the pathways used be the microRNAs that were selected for qPCR, we
used an online software MIR-Walk to compile the associations of these 7 microRNAs to the P53
pathway. MIR-Walk is a publicly available comprehensive resource, hosting the predicted as
well as the experimentally validated microRNA target interaction pairs. it also integrates many
novel features such as a comparative platform of microRNA-binding sites resulting from ten
different prediction datasets, a holistic view of genetic networks of microRNA–gene pathway,
and microRNA–gene–Online Mendelian Inheritance in Man disorder interactions, and unique
experimentally validated information such as cell lines, diseases, microRNA processing
proteins(Dweep, Gretz, & Sticht, 2014). Figures 4.5-4.9 located in the Appendix demonstrate
the individual roles each microRNA plays at specific steps in the P53 pathway.
According to Choudhury & Li et al, microRNA-21 and let-7 are two of the most studied
microRNAs (microRNAs), as the former is the most frequently up regulated and the latter is the
most frequently down-regulated in cancer (Choudhury & Li, 2012). Our initial data findings
from Partek Genomic Suite also indicated up regulation in microRNA-21 and let-7a as being
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down regulated in triple negative breast cancer. Up regulation of microRNA-21 suggests its role
in the enhancement of multiple oncogenic targets such as Ras, while a down-regulated let-7a is
suggested as a direct negative regulator of the Ras gene family. Our data shows a down
regulation of microRNA-34a in TNBC. D’Ippolito et al, demonstrates an under-expression of
microRNA-34a in the TNBC cell line in terms of migration(D'Ippolito & Iorio, 2013).
MicroRNA-103 expression was significantly higher in the cancer patients than in the healthy
control Group according to Xiaopai et al. Our data also indicates an up-regulation of microRNA103 in TNBC(Xiaopai & 2012). Our study indicates an up-regulation of microRNA-141 in
TNBC cell lines, which is consistent with research reported by Avery et al wherein microRNA141 is part of the microRNA-200 family and is significantly over-expressed (Avery-Kiejda,
Braye, Mathe, Forbes, & Scott, 2014).
4.2

To validate the microRNA expression level in Triple-Negative Breast Cancer cell

lines & Normal Breast Cancer cell line using Real-Time PCR
We subjected the cell lines to real-time PCR based on data obtained from Partek
Genomic Suite and literature reviews. We focused on 5 microRNAs; however, since three
microRNAs were listed from the Let-7 family we only used one of them. Figure 4.3 below
indicates the five primers that were used in the real-time PCR reactions.
Table 4.2 Primers used in Real-Time Polymerase Chain Reaction
Hsa-miR-21
Hsa-let-7a
Hsa-miR-34a
Hsa-miR-103
Hsa-miR-141
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Table 4.2 shows the primers associated with the 5 microRNAs which were chosen for
further evaluation using Real-Time PCR.
MicroRNA expression levels were indicated by g-mean signal values in Partek Genomic
Suite, and they are assessed by Cq values in Real-Time PCR reactions. Cq is a quantification
cycle that corresponds to a threshold cycle; the point where the fluorescence signal is high
enough to be differentiated from the background noise. The values representative of the
expression levels of the microRNAs are inverse of those found in Partek Genomic Suite.

Figure 4.10 Differentiating between Cq Values
Figure 4.10 identifies the relative relationship of the Cq values obtained in RT-PCR
Reactions. It demonstrates when there is more DNA or high expression levels then there are in
fact fewer cycles, which result in lower Cq values. However, when there is less DNA or lower
expression levels then more cycles occur, demonstrating higher Cq values.
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The figures below represents the relative Cq values in relation to the g-mean signal
values of the microRNA primers used the RT-PCR reactions.

Hsa-miR-21
miR-21

miR-21

miR-21

Average

AG11132

18.46

19.31

19.13

18.96667

HCC 1806

15.66

15.22

15.56

15.480

HCC 70

18.07

17.46

18.08

17.870

Figure 4.11 Real-Time PCR of microRNA-21 in TNBC cell lines vs. Normal Breast tissue cell
line.
Figure 4.11 demonstrates Cq values that are lower in the TNBC cell lines then in the
normal breast tissue cell lines. This indicates an up-regulation of microRNA-21 in the TNBC cell
lines (HCC 1806 &HCC70) vs. the normal breast tissue cell line (AG11132). According to
Dellago et al, microRNA-21 is described as being an oncogenic. This corresponds to increased
expression levels of this microRNA (Dellago et al., 2013). Accordingly, it confirms the results
described in figure 4.5 which demonstrates higher than normal breast tissue cell line expression
levels amongst the triple-negative breast cancer tissue cell lines.
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Figure 4.12 Statistical Analysis of RT- PCR Results of MicroRNA-21
Figure 4.12 demonstrates the p-values derived from the Cq values in RT-PCR. Here the
p-values were calculated using the average and standard deviation of the Cq values. The p-values
represent the amount of no change or difference, hence the smaller the p-value the more change
that is present and the larger the p-value, the less amount of change. Here we can see a small pvalue associated with both of our TNBC cell lines in comparison to our normal breast tissue cell
line. This demonstrates values that are statistically significant.

Hsa-let- 7a
miR let-7a

miR let-7a

miR let-7a

Average

AG11132

16.24

15.35

14.69

15.42667

HCC 1806

17.02

15.61

18.45

17.02667

HCC 70

18.29

18.45

17.90

18.21333

Figure 4.13 Real-Time PCR of let-7a in TNBC cell lines vs. Normal Breast tissue cell line.
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Figure 4.13 demonstrates Cq values that are higher in the TNBC cell lines then in the
normal breast tissue cell lines. This indicates a down-regulation in cancer consistent with results
from Partek Genomic Suite. Let-7a is microRNA described as a heterochronic gene which serves
as a tumor suppressor by targeting various oncogenic pathways in cancer cells as stated by (Hu et
al., 2013). This demonstrates let-7a as microRNA with reduced expression, notably consistent
with the results gathered from our study which indicate down-regulation of this microRNA in
TNBC cell lines in comparison to the normal breast tissue cell line in the study.

Figure 4.14 Statistical Analysis of RT- PCR Results of MicroRNA-let-7a
Figure 4.8 demonstrates the p-values derived from the Cq values in RT-PCR. Here the pvalues were calculated using the average and standard deviation of the Cq values. The p-values
represent the amount of no change or difference, hence the smaller the p-value the more change
that is present and the larger the p-value, the less amount of change. Here we can see a small pvalue associated with only one of our TNBC cell lines in comparison to our normal breast tissue
cell line. This suggestion that one of the TNBC cell lines are not statistically significant, it
indicates that more research should be done to further validate our findings.
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Hsa-miR-34a
miR-34a

miR-34a

miR-34a

Average

AG11132

25.04

25.28

25.62

25.31333

HCC 1806

25.32

25.14

24.79

25.08333

HCC 70

27.58

27.03

27.19

27.26667

Figure 4.15 Real-Time PCR of microRNA-34a in TNBC cell lines vs. Normal Breast tissue cell
line.
Figure 4.15 demonstrates Cq values that are higher in the TNBC cell lines then in the
normal breast tissue cell lines. This indicates a down-regulation in cancer consistent with results
from Partek Genomic Suite. Misso et al, describes microRNA-34a as a key regulator of tumor
suppression, as it has the ability to control the expression of a plethora of target proteins with
implications in the cell cycle, differentiation and apoptosis(Misso et al., 2014). The role of
microRNA-34a as a tumor suppressor demonstrates lower expression levels in the TNBC cells.

Figure 4.16 Statistical Analysis of RT- PCR Results of MicroRNA-34a
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Figure 4.16 demonstrates the p-values derived from the Cq values in RT-PCR. Here the
p-values were calculated using the average and standard deviation of the Cq values. The p-values
represent the amount of no change or difference, hence the smaller the p-value the more change
that is present and the larger the p-value, the less amount of change. Here we can see a small pvalue associated with only one of our TNBC cell lines in comparison to our normal breast tissue
cell line. This suggestion that one of the TNBC cell lines are not statistically significant, it
indicates that more research should be done to further validate our findings.

Hsa-miR-103
miR-103

miR-103

miR-103

Average

AG11132

27.28

28.50

26.76

27.51333
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19.80

21.59

19.85

20.41333

HCC 70

19.69

21.16

20.66

20.50333

Figure 4.17 Real-Time PCR of microRNA-103 in TNBC cell lines vs. Normal Breast tissue cell
line.
Figure 4.17 demonstrates Cq values that are lower in the TNBC cell lines then in the
normal breast tissue cell lines. This indicates an up-regulation in cancer consistent with results
from Partek Genomic Suite and literature reviews. According to Martello et al the microRNA
family 103/107 displays high expression levels which are associated with metastasis and poor
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outcome (Martello et al., 2010). These results are consistent with our findings which indicate
microRNA-103 as a microRNA which is expressed at higher than normal level in TNBC cell
lines in comparison to the normal breast tissue cell line.

Figure 4.18 Statistical Analysis of RT- PCR Results of MicroRNA-103
Figure 4.18 demonstrates the p-values derived from the Cq values in RT-PCR. Here the
p-values were calculated using the average and standard deviation of the Cq values. The p-values
represent the amount of no change or difference, hence the smaller the p-value the more change
that is present and the larger the p-value, the less amount of change. Here we can see a small pvalue associated with both of our TNBC cell lines in comparison to our normal breast tissue cell
line. This suggestion that both of the TNBC cell lines are statistically significant, it indicates that
this study demonstrate consistently relevant comparison of microRNA expression in TNBC cell
lines compared to the normal breast tissue cell line.
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Figure 4.19 Real-Time PCR of microRNA-141 in TNBC cell lines vs. Normal Breast tissue cell
line.
Figure 4.19 demonstrates Cq values that are lower in the TNBC cell lines then in the
normal breast tissue cell lines. This indicates an up-regulation in cancer consistent with results
from Partek Genomic Suite. microRNA-141 is part of the microRNA-200 family, studies such as
Chang et al indicate an over-expression of this microRNA in breast cancer which promotes
metastasis and drug resistance(Chang et al., 2012). Results from this study compare with the
results from our study in regards to the increased expression levels of microRNA-141 in TNBC.

Figure 4.20 Statistical Analysis of RT- PCR Results of MicroRNA-141
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Figure 4.20 demonstrates the p-values derived from the Cq values in RT-PCR. Here the
p-values were calculated using the average and standard deviation of the Cq values. The p-values
represent the amount of no change or difference, hence the smaller the p-value the more change
that is present and the larger the p-value, the less amount of change. Here we can see a small pvalue associated with both of our TNBC cell lines in comparison to our normal breast tissue cell
line. This displays statistical significance i only of the TNBC cell lines. While it is consistent
with the finding of this study, it demonstrates the need for further testing of this miRNA for
increased validity.
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CHAPTER 5
DISCUSSION & FUTURE RESEARCH
In this report we have compared the microRNA expression profiles from microarray and
qPCR analysis on triple-negative breast cancer and normal breast tissue cell lines. MicroRNA
expression profiles revealed a differential expression pattern in triple-negative breast cancer cells
when compared to normal breast tissue cells. Amongst the cell lines, the microRNA expression
profiles for the triple-negative breast cancer cells lines display values lower (down-regulated) or
higher (up-regulated) than those of normal breast tissue cells. Previous research reports suggest
that over or under expression of microRNAs have a significant impact on the expression of
protein-coding genes. MicroRNAs have the ability to play a role in regulation of gene expression
or in tumorgenesis, by acting as oncogenes or tumor suppressors (Buffa et al., 2011). Other
reports have described altered expression of microRNAs in cancer tissues compared to normal
tissues, suggesting that these microRNAs could potentially represent novel clinical and
prognostic markers (Carey et al., 2006). This research is novel because of its usage of cell lines
that could serve as model systems to investigate deeper molecular level potential TNBC
biomarkers and drug therapeutic target. The findings may help to provide individualized
therapeutic options based on the microRNA expression profile of a TNBC patient. Additionally,
it also reduces the percent error, since there are not multiple patient data sets involved. The usage
of Partek Genomic Suite to find microRNA expression profiles, followed by validation of these
results by real-time PCR will help to substantiate the claims that microRNAs can be used to
determine treatment, prognostic, and diagnostic options for individuals with TNBC and other
debilitating diseases.

45
We have shown here with the microRNA analysis of TNBC cells compared to normal
breast cells that there are some indications of differences in the expressions of some microRNAs.
These microRNAs have been shown to play an influential role in the pathways associated with
many diseases, including, but not limited to breast cancer. For example, our study has shown that
microRNA-21 is over-expressed in cancer cell lines. Previous studies have suggested that
microRNA-21 has a prognostic value in patients with cancer (Gazinska et al., 2013).
Additionally, it has also been found that high expression of microRNA-21 mi According to
Gazinska et al triple-negative breast cancer is associated with lesions that are characterized by a
high incidence of TP53 mutations, as well as low levels of RB and high levels of p16 proteins
might predict poor prognosis in patients with colorectal cancer (D'Ippolito & Iorio, 2013). Our
study also demonstrated a decrease in expression in microRNA let-7a. These findings are
consistent with a proposed repression of let-7 in cancer from Choudhury and Li (2012).
MicroRNA-34a was found to be down-regulated in breast cancer cell lines and tissues, compared
with normal cell lines and the adjacent non-tumor tissues, respectively (Li et al., 2012). Our
study also demonstrated a down-regulation of microRNA-34a. Martello et al, suggests in human
breast cancer, high levels of microRNA-103/107 are associated with metastasis and poor
outcome (Martello et al., 2010). Data from our study reports an up-regulation of microRNA-103
amongst TNBC cells compared to normal breast tissue cells. Studies such as Avery et al and
Chang et al, validate the finding of this study in relation to an up-regulation of microRNA-141 in
cancer, however other studies such as Iorio et al and Eades et al, suggest the down-regulation of
this microRNA in cancer.
These findings continue to support the role of microRNAs not just breast cancer, but
other cancer types as well show roles of microRNAs as therapeutic, prognostic, and therapeutic
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biomarkers. The findings from these this study also demonstrated the importance of microRNAs
in cancer, specifically triple-negative breast cancer. The usage of complete cell lines will also
create a platform for other research studied to be performed on. Additionally, a reduction in
errors also prevalent due to the usage of individual cells lines, rather than studies with many
participants.
Future directions include utilization of breast cell lines from Caucasian Women using the
same methodology and comparison to African-American Women in order to derive a better
understanding of the differences in expression levels of microRNAs normal and triple-negative
breast cell lines between these groups of women. Additionally, determination of the roles of
these miRNAs using different treatment methods will help to demonstrate the role and efficacy
of these microRNAs.
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Appendix

Figure 4.4 Pathway Enrichment Analyses from Partek Genomic Suite
Figure 4.4 depicts the pathways associated with the microRNAs found on the microarray
chip. This figure was created using Pathway Enrichment Analysis in Partek Genomic Suite. It
identifies some of the pathways in which specific microRNAs have been known to interact with
genes and proteins. MicroRNA-21 is listed on this diagram demonstrating its role in cell growth
and survival.
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Table 4.3 Display 32 differentially expressed microRNAs from Partek Genomic Suite

Table 4.3 displays the 32 differentially expressed microRNAs that were found using
Partek Genomic Suite. All of these microRNAs have been shown in literature to play a role in
cancer, however, only certain one have a role in Triple-Negative Breast Cancer.
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Hsa-miR-103

Figure 4.5P53 Pathway Hsa-microRNA-21
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Hsa-let-7a

Figure 4.6P53 Pathway Hsa-let-7a
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Figure 4.7P53 Pathway Hsa-microRNA-34a
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Figure 4.8P53 Pathway Hsa-microRNA-103
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Figure 4.9P53 Pathway Hsa-microRNA-141

